Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A comparison of three medications to treat diarrhea in adults.
This single (investigator) blind, randomized, 3-arm, parallel-group study design was selected to show non-inferiority of loperamide/simeticone caplets compared to chewable tablets in a heterogeneous subject population aiming at validity of results and reducing bias. The study will also compare the loperamide/simeticone combinations versus a probiotic (Saccharomyces boulardii) in the treatment of acute diarrhea in adults. Probiotics have been used for acute infectious diarrhea to reduce the duration and severity of the illness.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Loperamide/simeticone Caplets | Experimental | Drug (including placebo) |
|
| Loperamide/simeticone Chewable Tablets | Active Comparator | Drug (including placebo) |
|
| Probiotic Capsules | Active Comparator | Drug (including placebo) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Loperamide/simeticone 2 mg/125 mg caplets | Drug | Oral, 2 caplets taken initially at investigator site followed by one caplet after each unformed stool, maximum 4 caplets in a 24 hour period for a maximum of 48 hours (per product label) |
| Measure | Description | Time Frame |
|---|---|---|
| Number of unformed stools | 0-24 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Number of unformed stools | 0-12, 12-24, 24-36, 36-48 hours | |
| Time to last unformed stool | Throughout duration of the study | |
| Time to complete relief of abdominal discomfort |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Elisabeth Kruse, PhD | McNeil AB | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Manipal Goa Hospital | Mormugao | Goa | 403004 | India | ||
| Vrundavan Hospital & Research Centre |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 26541878 | Derived | Cottrell J, Koenig K, Perfekt R, Hofmann R; Loperamide-Simethicone Acute Diarrhoea Study Team. Comparison of Two Forms of Loperamide-Simeticone and a Probiotic Yeast (Saccharomyces boulardii) in the Treatment of Acute Diarrhoea in Adults: A Randomised Non-Inferiority Clinical Trial. Drugs R D. 2015 Dec;15(4):363-73. doi: 10.1007/s40268-015-0111-y. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003967 | Diarrhea |
| ID | Term |
|---|---|
| D012817 | Signs and Symptoms, Digestive |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D008139 | Loperamide |
| D012841 | Simethicone |
| ID | Term |
|---|---|
| D010880 | Piperidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D004129 | Dimethylpolysiloxanes |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Loperamide/simeticone 2 mg/125 mg chewable tablets | Drug | Oral, 2 chewable tablets taken initially at the site followed by one chewable tablet after each unformed stool, maximum 4 chewable tablets in a 24 hour period for a maximum of 48 hours (per product label) |
|
|
| Probiotic Saccharomyces boulardii 250 mg capsules | Drug | Oral, 1 capsule twice a day, maximum 2 capsules in a 24 hour period for a maximum of 5 days (per product label) |
|
|
| Throughout duration of the study |
| Time to complete relief of diarrhea | Throughout duration of the study |
| Proportion of subjects with complete relief of diarrhea | 4, 8, 12, 24 and 48 hours |
| Gas-related abdominal discomfort ratings - change from baseline at subsequent time points | Throughout duration of the study |
| Proportions of subjects with complete well-being | at 12, 24 and 48 hours. |
| Subject's evaluation of treatment effectiveness for overall illness relief, diarrhea relief and abdominal discomfort relief | Throughout duration of the study |
| Number of loperamide/simeticone 2 mg/125 mg caplets or chewable tablets or probiotic (Saccharomyces boulardii) 250 mg capsules used during the study | Throughout duration of the study |
| Frequency of complete well-being following diarrhea illness | at 7 days follow up |
| Stool frequency | at 7 days follow up |
| Frequency of diarrhea relapse | at 7 days follow up |
| Safety Assessments will consist of monitoring and recording all non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs), their frequency, severity, seriousness, and relationship to the investigational product. | throughout duration of the study (+ 30 days for spontaneously-reported SAEs) |
| Mormugao |
| Goa |
| 403527 |
| India |
| North West Medical | San José del Cabo | Baja California Sur | 22447 | Mexico |
| Dr. Maxwell´s Clinic | San Miguel de Allende | Guanuajuato | 37700 | Mexico |
| Hospital Amerimed Puerto Vallarta | Puerto Vallarta | Jalisco | 48300 | Mexico |
| Servicios Medicos de la Bahia | Puerto Vallarta | Jalisco | 48300 | Mexico |
| D012828 | Silicones |
| D012833 | Siloxanes |
| D017646 | Organosilicon Compounds |
| D009930 | Organic Chemicals |
| D011108 | Polymers |
| D046911 | Macromolecular Substances |
| D001697 | Biomedical and Dental Materials |
| D008420 | Manufactured Materials |
| D013676 | Technology, Industry, and Agriculture |